Drug reference
quiniodochlor
Other topical agents · Antifungal, Amoebicide
Other topical agentsAntifungal, Amoebicide
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Quiniodochlor has weak antifungal and antibacterial activity.
Indications
Dermatophytosis (external application)Mycosis barbae (external application)Seborrhoeic dermatitis (external application)Infected eczema (external application)Furunculosis (external application)Pityriasis versicolor (external application)Monilial vaginitis (in vaginal creams)Trichomonas vaginitis (in vaginal creams)Intestinal amoebiasis (alternative to diloxanide furoate)GiardiasisLocal treatment of monilial vaginitisLocal treatment of trichomonas vaginitisLocal treatment of fungal skin infectionsLocal treatment of bacterial skin infections
Dosing
- Adult
- 250–500 mg TDS (not to exceed 1.5 g/day for 14 days).
Pharmacokinetics
Half-life
~12 hours.
Bioavailability
Absorption from the intestine is variable.
Metabolism
The absorbed fraction is conjugated in liver with glucuronic acid and sulfate.
Excretion
Excreted in urine.
Contraindications
- pediatric patients (in India)
- fixed dose combinations (except for external application) banned in India
- high doses for more than 14 days
Side effects
Common
nauseatransient loose and green stoolspruritus
Serious
- iodism (furunculosis, inflammation of mucous membranes)
- goiter (due to chronic iodine overload)
- acute reaction (chills, fever, angioedema, cutaneous haemorrhages) in iodine-sensitive individuals
- subacute myelo-optic neuropathy (SMON) (caused by prolonged/repeated high doses)
- neuropathy
- visual impairment
- blindness (in children with chronic use)
Related guidelines
Ask House about quiniodochlor
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team